


## AMENDMENTS TO THE CLAIMS


Claims 1 to 28 (cancelled)

Claim 29 (currently amended)


A carbohydrate peptide conjugate ~~comprising a dendrimeric poly lysine carrier~~  
~~enabling multiple epitopes B and T to be covalently attached thereto, wherein said~~  
~~carbohydrate peptide conjugate~~ is selected from the group consisting of the conjugates of  
the following formulae




(B4-T4-M)



(B2-T2-M)



(B8-T8-M)



(B4-T4-M)

wherein:

- B denotes a structurally defined carbohydrate moiety which is a tumor antigen, or a derivative thereof, containing B epitope other than a ~~sialoside~~ sialoside, or several identical or different B epitopes;
- T denotes a peptide comprising one CD4<sup>+</sup> T epitope or several identical or different T-epitopes;
- K denotes a lysine ~~from 1 to 13~~ residue;
- n is an integer from 1 to 13;
- m is an integer from 1 to 9; and

wherein the B and T groups are covalently attached to the poly-lysine carrier.

**Claim 30** (previously presented)

A conjugate of claim 29 wherein the carbohydrate moiety is galactosyl.

**Claim 31** (currently amended)

A conjugate of claim 29 which comprises 3 lysine residues, at least 2 CD4<sup>+</sup> T cell epitopes, which may be the same or different, linked to the NH<sub>2</sub> ends of 2 of the lysine residues and 4 α-galactosyl-N-acetyl-Serine residues.

**Claim 32** (previously presented)

A conjugate of claim 29 wherein the carbohydrate moiety is a galactosyl residue and is substituted with a glycosyl residue.

**Claims 33 – 34** (cancelled)

**Claim 35** (cancelled)

**Claims 36 – 37** (cancelled)

**Claim 38** (previously presented)

A conjugate of claim 29 wherein the carbohydrate is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T<sup>\*</sup> antigen and hexa-Tn antigen.

**Claim 39** (previously presented)

A pharmaceutical composition comprising the conjugate of claim 29 and a suitable carrier and adjuvant.

**Claim 40** (previously presented)

A vaccine comprising the conjugate of claim 29.

**Claim 41** (cancelled)

**Claim 42** (previously presented)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 29 wherein said composition is capable of increasing the survival of a tumor bearing human or animal.

**Claim 43** (currently amended)

An immunogenic composition comprising at least one carbohydrate conjugate of claim 42 wherein said conjugate comprises different carbohydrate antigens ~~to induce more efficient anti tumor immunity against cancers.~~

**Claim 44** (currently amended)

A method of inducing an immune response to at least one member of the group consisting of B-cells and CD4<sup>+</sup> T-cells in a human or animal body, wherein the conjugate of claim 29 is administered to said human or animal body.

**Claims 45** (cancelled)

**Claim 46** (cancelled)

**Claim 47** (previously presented)

A method of vaccination of a human or animal body wherein the conjugate of claim 29 is administered to said human or animal body.